research reports and media, page-3390

Horizon Therapeutics prospective price to revenue is around 30:1.

From liveware markets back in 2020....
"Both MPS and OA could independently be a company maker, with the addressable market for
MPS being estimated to be around $1 billion per annum,
and the target market globally for OA being between $18 and $36 billion p.a. "

That's potential revenue.

But MPS is about where Zilosol was 2 years ago, when PAR was worth about $0.6b MC, or roughly half that now.

So what would be a good price for MPS without any revenue? Not so much. You have to divide the share price for (Zilosul (30b) + MPS (1b))/31
Then account for no revenue.

So either that is realistic, or PAR's share price now (and 2 years back), isn't. And the reason why its current low price (as we see it) is realistic is that there is no revenue and that the market is marking down ageing unicorns.

Which is why we should be pressuring the Board to get a move on with TGA.